AACP
IBRX icon

Advantage Alpha Capital Partners’s ImmunityBio IBRX Stock Holding History

Advantage Alpha Capital Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-69,207
Closed -$257K – 168
2024
Q3 		$257K Buy
+69,207
New +$320K 0.06% 164

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advantage Alpha Capital Partners's IBRX Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of ImmunityBio (IBRX) in Q4 2024, closing a stake of 69,207 shares — an estimated $257K sold.

Advantage Alpha Capital Partners first reported a position in IBRX in Q3 2024 and held it in 1 quarter. The position peaked at $257K in Q3 2024. 201 funds tracked by Wall St. Rank hold IBRX as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining ImmunityBio position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 69,207 ImmunityBio shares in Q4 2024, an estimated $257K.
  • Advantage Alpha Capital Partners first reported a position in ImmunityBio in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's ImmunityBio position peaked at $257K in Q3 2024.
  • 201 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.